Cancer Therapeutics Program

癌症治疗计划

• 批准号: 10627031
• 负责人: Lacey R McNally
• 金额: $ 5.24万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10627031
• 关键词: Address; Advanced Malignant Neoplasm; Area; Artificial Intelligence; Biomedical Engineering; Biotechnology; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Detection; Cancer Diagnostics; Catchment Area; Categories; Cessation of life; Clinical; Clinical Cancer Center; Clinical Research; Clinical Trials; Collaborations; Community Outreach; Computational algorithm; Contrast Media; Data Analyses; Dedications; Development; Devices; Diagnostic; Diagnostic Procedure; Direct Costs; Doctor of Philosophy; Drug Delivery Systems; Fostering; Funding; Goals; Grant; Growth; Hematologic Neoplasms; Home; Human; Image; Imaging technology; In Vitro; Incidence; Infrastructure; Institution; Intervention; Journals; Laboratories; Malignant Neoplasms; Manuscripts; Medicine; Nanodelivery; Oklahoma; Oncology; Patient-Focused Outcomes; Patients; Peer Review; Positioning Attribute; Preclinical Testing; Process; Publications; Publishing; Race; Reporting; Research; Research Activity; Research Peer Review; Research Personnel; Risk; Scientist; Signal Pathway; Solid Neoplasm; Systems Analysis; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Clinical Trial; Translating; Translational Research; Translations; United States; cancer diagnosis; cancer therapy; cancer type; community engagement; contrast imaging; delivery vehicle; diagnostic algorithm; early phase clinical trial; fundamental research; imaging modality; improved; in vivo; innovation; member; mortality; nanoparticle; new therapeutic target; novel; novel anticancer drug; novel therapeutics; programs; success; targeted agent; therapeutic evaluation; translational medicine; treatment trial

CANCER THERAPEUTICS PROGRAM: ABSTRACT The overarching goal of the Cancer Therapeutics (CT) program is to translate discoveries through: 1) development of new therapeutic agents, 2) biotechnology and bioengineering approaches, and 3) innovative clinical trials in order to enhance cancer diagnosis and treatment and improve patient outcomes. CT is a new program in this CCSG application, resulting from the significant growth of clinical and translational research across solid and hematologic tumors and a strategic realignment of the SCC’s former three programs. It better positions the SCC for strategically driven growth in these areas and allows for greater catchment area impact. The CT program is led by Lacey McNally, PhD and Kathleen Moore, MD, who bring complementary expertise in developing agents and technologies and translating these into clinical trials that can have a positive impact on patients with cancer. In 2021, the CT program had 38 members (23 full, 15 associate), representing 13 academic departments at two campuses (31 at OUHSC; 7 at OU Norman). Of these 38 members, 20 are MDs, underscoring the need to have a programmatic home within the SCC for clinical trialists and clinician scientists focused in all cancer types. An additional 75 CT affiliate members (non-CCSG category), including many SCC clinician investigators, help advance CT program aims. Total peer-reviewed research funding was $6.54M, of which $4.33M was from NCI (annual, direct cost). Significantly, NCI funding accounts for 66% of total peer-reviewed funding, highlighting the strong cancer-focus of the CT program. Total peer-reviewed research funding increased by 29% over the grant cycle ($5.06M to $6.54M), with NCI increasing by 34% ($3.23M to $4.33M). The number of peer-reviewed projects rose from 23 (2017) to 35 (2021), a 52% increase highlighting programmatic growth and diversity of research activity. CT members published 755 manuscripts in peer- reviewed journals over the past five years (3.97 / member / year). Of these, 154 (20%) were intra- programmatic, 190 (25%) were inter-programmatic, and 570 (75%) were multi-institutional, demonstrating the high degree of collaboration between CT members, with members in other SCC programs, and with investigators at other institutions. Importantly, 161 (21%) of CT member publications were published in high- impact journals (impact factor ≥10). During the reporting period, 3,652 patients were accrued to CT clinical trials, including 3,095 to interventional treatment trials. The number of annual active CT member interventional treatment IITs increased from 4 (2017) to 21 (2021), highlighting the expanding depth and breadth of translational activity emanating from the program.

癌症治疗计划：摘要 癌症治疗 (CT) 计划的总体目标是通过以下方式转化发现：1) 新治疗剂的开发，2) 生物技术和生物工程方法，以及 3) 创新 临床试验旨在加强癌症诊断和治疗并改善患者预后。 CT是一种新的 CCSG 申请中的计划，源于临床和转化研究的显着增长 跨越实体瘤和血液肿瘤以及 SCC 前三个项目的战略调整。更好 SCC 定位于这些领域的战略驱动增长，并允许更大的集水区影响。 CT 项目由莱西·麦克纳利 (Lacey McNally) 博士和凯瑟琳·摩尔 (Kathleen Moore) 医学博士领导，他们带来了互补 开发药物和技术并将其转化为临床试验的专业知识 对癌症患者产生积极影响。 2021 年，CT 项目有 38 名成员（23 名正式成员，15 名副成员），代表 13 个学术部门 两个校区（31 个位于 OUHSC；7 个位于 OU Norman）。在这 38 名成员中，20 名是常务董事，这强调了需要 在 SCC 内为专注于所有癌症的临床试验人员和临床科学家提供一个程序化的家 类型。另外 75 名 CT 附属成员（非 CCSG 类别），包括许多 SCC 临床医生 研究人员，帮助推进 CT 计划目标。同行评审研究经费总额为 654 万美元，其中 433 万美元来自 NCI（年度直接成本）。值得注意的是，NCI 资助占同行评审资助总额的 66% 资金，突出了 CT 项目对癌症的强烈关注。同行评审研究经费总额 在拨款周期内增加了 29%（506 万美元至 654 万美元），其中 NCI 增加了 34%（323 万美元至 433 万美元）。 同行评审项目的数量从 23 个（2017 年）增加到 35 个（2021 年），增加了 52%，突显了 研究活动的计划性增长和多样性。 CT 成员在同行中发表了 755 篇手稿 过去五年审阅的期刊（3.97/会员/年）。其中，154 人 (20%) 是内部人员 其中 190 个（25%）是跨项目的，570 个（75%）是跨机构的，这表明 CT 成员、其他 SCC 项目的成员以及 其他机构的调查员。重要的是，161 篇（21%）的 CT 成员出版物发表在高水平期刊上。 影响力期刊（影响因子≥10）。报告期内，共有3,652名患者接受CT临床检查 试验，包括 3,095 项介入治疗试验。年度活跃CT会员介入人数 治疗个人所得税从 4 个（2017 年）增加到 21 个（2021 年），凸显了治疗深度和广度的不断扩大 源自该计划的翻译活动。